One cupcake won't kill you', 'I'm going to get diabetes just looking at that', 'That person doesn't look like they have ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

Abbott has launched Above the Bias, a global initiative to drive awareness about the health impact that common misconceptions and bias about diabetes can have on people living with ...

AbbottAs a competitive powerlifter, Nathan Zenero has a unique talent for lifting heavy things. He's also taken on more than a few challe ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

The company's Q3 profir increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...